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Abstract 
	
	
  
Background and purpose 
 
For patients with glioblastomas the standard therapy is represented by maximal 
safe tumor resection followed by concurrent chemoradiotherapy with 
temozolomide (TMZ) and adjuvant TMZ. Determination of the response to 
therapy is entirely dependent on the interpretation of magnetic resonance (MR) 
imaging findings and clinical manifestations. 
The purpose of this study was to assess the utility of MR advanced techniques 
such as diffusion (DWI) and perfusion (PWI) imaging in predicting response or 
progression of gliomas to chemoradiotherapy. 
 
Materials and methods 
 
We retrospectively selected 32 patients with high grade glioma treated with 
surgical resection followed by radiation therapy and temozolomide who 
underwent conventional MR imaging and advanced MR techniques before 
surgery (T0), before (T1) and after RT (T2). By using the RANO criteria at T2, 
the patients were divided into two groups, “progression” and “response”. Pre 
and postcontrastographic T1-weighted images were coregistered with the 
Apparent Diffusion Coefficient (ADC) and PWI maps . Contrast Enhancement, 
permeability (PSR), minimum value of ADC and maximum value of relative 
Cerebral Blood Volume (rCBV) were calculated with a ROI method at T0, T1 
and T2 and used as variables. In conventional MRI we calculated the 
incremental ratio of the size of the pre and post operative tumor. 
Unpaired t-test was used to test difference between groups for the above-
mentioned variables for each time point. Significant data were utilized in the 
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univariate logistic regressions in order to determine odds ratios for assessing 
risk factors. A multivariate logistic regression was performed on univariate 
significative variables. 
 
Results 
 
At unpaired t-test ADC, PSR and rCBV at T1 presented statistical significant 
differences between the two groups. For the group “progression” the univariate 
logistic regressions with these variables, adjusted for gender and age, identified 
ADC and rCBV as predictors of progression while in the subsequent 
multivariate logistic regression only ADC showed statistical significance as 
predictor. For the group “response” the univariate logistic regressions with 
these variables, adjusted for gender and age , identified ADC, rCBV and PSR 
as predictors of response while in the subsequent multivariate logistic 
regression only PSR showed statistical significance. 
 
Conclusions 
 
MR advanced techniques, in particular diffusion with ADC and perfusion with 
PSR, have proved a valuable aid in predicting respectively progression and 
response of glioblastomas to chemoradiotherapy. 
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                                           Introduction 
 
 
 
Glioblastoma multiforme (GBM) is the most common primary malignant brain 
tumor in adults, accounting for approximately one percent of all tumors. 
Despite the evaluation of multiple treatment approaches, the prognosis for 
patients with GBM is still extremely poor, with an estimated median survival 
of 9-18 months [1,2]. Currently, maximal safe tumor resection followed by 
concurrent chemoradiotherapy (CCRT) with temozolomide (TMZ) and 
adjuvant TMZ is the standard therapy for patients with GBM [3]. 
Determination of the response to therapy is entirely dependent on the 
interpretation of magnetic resonance (MR) imaging findings and clinical 
manifestations [4]. 
In 1990, Macdonald introduced radiological and clinical response criteria for 
malignant brain tumours [5]. These criteria provide a standardized radiological 
assessment of the tumour response and are based on measuring the enhancing 
component of the tumour. The enhancing portion of GBM is a key factor for 
using these criteria to predict the prognosis of GBM patients. Furthermore, in 
2010, the Response Assessment in NeuroOncology (RANO) Working Group 
proposed new standardized criteria for accurately assessing the tumor response 
in high-grade glioma patients [6]. The RANO criteria emphasize not only the 
evaluation of the non-enhancing component but also precise examination of 
measurable enhancing tumor components. The measurable enhancing lesions 
are defined as bidimensionally contrast-enhancing lesions with clearly defined 
margins by computed tomography (CT) or MRI scans and two perpendicular 
diameters of at least 10 mm visible on two or more axial slices that are 
preferably, at most, 5 mm apart with 0-mm skip [6,7]. 
The use of these criteria allows to establish the presence of progression or 
response only after chemoradiotherapy. 
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The availability of predictors of progression or response before starting the 
therapy would be helpful to know patient prognosis [8], to avoid futile care and 
to reduce the risk of any side effects to the patient. 
In recent years several genetic markers able to predict the response of the 
patient to therapy have been identified [9-11]. 
Also MR imaging with advanced techniques has been tested, triyng to predict 
the prognosis for patients with high-grade glioma [12-18]. 
The purpose of this study was to assess the utility of DWI and DSC perfusion 
imaging in predicting response or progression of glioma to chemoradiotherapy.  
 
 
 
 
 
 
Materials and Methods 
 
 
 
Patient selection criteria and clinical data collection 
 
In this retrospective study the patient cohort consisted in 32 patients with High 
Grade Glioma (HGG) according to the following inclusion criteria: 1) 
histological diagnosis of glioblastoma or anaplastic astrocytoma obtained on 
surgical specimen performed in our center, 2) treatment with RT and 
temozolamide, 3) brain MRI imaging, including contrast T1-weighted imaging, 
DWI and/or DSC perfusion before surgery (T0), after surgery before RT (T1) 
and after RT (T2). 
The lack of one of the mentioned criteria constitutes cause of exclusion from 
the retrospective study. 
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The 32 patients were 22 women and 10 men with median age of  55.1 years 
(range 27-78 years).  All patients were affected by HGG, in particular by 
glioblastoma (n = 84.4%) and anaplastic astrocitoma (n =15.6%).  
At initial diagnosis, patients underwent gross total resection of the tumours 
(n=7) or partial resection of the tumour (n=16).  
Radiotherapy consisted of fractionated focal irradiation at a dose of 2 Gy per 
fraction given once daily five days per week over a period of six weeks, for a 
total dose of 60 Gy. Radiotherapy was delivered to the gross tumour volume 
with a 2-to-3-cm margin for the clinical target volume. Radiotherapy was 
planned with dedicated computed tomography (CT) and three-dimensional 
planning systems; conformal radiotherapy was delivered with linear 
accelerators with nominal energy of 6 MV or more, and quality assurance was 
performed by means of individual case reviews. All patients received 
concomitant temozolomide at standard dose. 
Patients were followed along the time to register clinical changes and to 
determine overall survival. 
The patients were divided into two main groups, “progression” and “response” 
groups, on the basis of RANO criteria applied at T2  and in subsequent follow-
up MR examinations. According to these criteria 17 patients were identified as 
belonging to group “progression” and 12 patients belonging to group 
“response”. 3 patients were classified in a separate group denominate 
“pseudoprogression”, on the basis of the behaviour of the enhancing lesion in 
the post- radiotherapy period. These patients had a worsening of the 
neuroradiological picture at T2  with a tumoural regression in the subsequent 
MR examination. 
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MRI examination protocol and Image evaluation 
 
Conventional MRI 
 
MRI examinations were performed on 1.5 T and 3 T MR system (Signa and 
Discovery 750, GE Healthcare, Milwaukee, Wisconsin) with a quadrature head 
coil. After triplanar scout view, the MRI examination protocol consists of pre-
contrast conventional MRI followed by DWI, MRS and PWI, and finally post-
contrast T1 weighted images. 
 Conventional MR examination consisted in axial fluid-attenuated inversion 
recovery images (FLAIR, TR 10000 msec, TE 100 msec, TI 2000 msec, FOV 
24 cm, Tk 5 mm, gap 1 mm, NEX 1, matrix 192 x 256, acquisition time 
4’35’’), axial spin-echo T1-weighted (TR 500  msec, TE 9.4 msec, FOV 22, Tk 
4 mm, gap 1 mm, NEX 2) and axial fast spin-echo T2-weighted (TR 4930 
msec, TE 104 msec, FOV 22, Tk 4 mm, gap 1 mm, NEX 2) images. After 
contrast media administration high resolution volumetric images with T1-
weighted SPGR sequence (TR 2160 msec, TE 3.9 msec, TI 1100 msec, FOV 
25.6, Tk 1.2 mm, gap 0 mm, NEX 1) and spin echo axial T1 weighted 
sequences were obtained. 
 
Post contrast T1-weighted images and T2-weighted images were used to apply 
RANO criteria in order to group patients in “progresssion” and “response”. In 
particular patients who met any one of following criteria were classified as 
having progressive disease: (a) >25% increase in the sum of the products of the 
perpendicular diameters of enhancing lesions with the smallest tumor 
measurement; (b) any new lesion; (c) clear clinical deterioration not 
attributable to other causes apart from the tumor; (d) failure to return for 
evaluation as a result of death or deteriorating condition; and (e) clear 
progression of non-measurable disease.  
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Axial precontrast and post contrast T1-weighted images were subsequently 
coregistered and the section containing the maximum diameter of the 
enhancing lesion was selected for subsequent ROI analysis. We drew a small 
circular ROI in the enhancing lesion to obtain the highest signal value (S) and 
we duplicate the circular ROI in the same region of pre-contrast image (S0). 
These values were then used to calculate the Contrast Enhancement  (CE) = S-
S0/S0 as incremental ratio.  
 
 By using conventional MRI we also calculated the incremental ratio of the size 
of the pre and post operative tumour. In axial postcontrast T1-weighted image 
at T0 we obtained tumoral size considering only misurable lesions according to 
RANO criteria (enhancing lesions with diameter >1cm) multiplying the largest 
diameter to the diameter perpendicular to it (Figure 1). We used a similar 
procedure to misure tumoral size in the postcontrast T1 weighted image at T1 
after surgery.  Then using the formula ((sizeT0 - sizeT1)/sizeT0) we obtained 
incremental ratio of tumoral size. 
 
 
 
Figure 1. Application of RANO criteria for measurable lesions. Tumoural size is obtained 
multiplying the largest diameter to the diameter perpendicular to it. 
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DWI 
 
DWIs were acquired before contrast media administration using echoplanar 
imaging (EPI) sequences (TR 4300, TE 97, FOV 24, thickness 4 mm, spacing 
1,2 mm, NEX 3, matrix 128 x 128, acquisition time 1’15’’) implemented by 
diffusion gradients (b = 0, 1000 s/mm2) in three or six orthogonal directions. 
The DWI data were transferred together with the anatomic data to a 
workstation (Advantage Workstation, GE Healthcare) and were analysed by 
using commercial software (FuncTool, GE Healthcare). ADC maps were 
calculated and coregistrated with the axial precontrast and post contrast T1-
weighted images and with Cerebral Blood Volume (CBV) maps. The contrast 
images were inspected and the section containing the maximum diameter of the 
enhancing lesion was selected for subsequent ROI analysis. We drew a small 
circular ROI (approximately 20 mm2) within the enhancing lesion that was 
adjusted onto the ADC map as necessary to target areas with visually low ADC 
values; the value obtained was recorded as ADC ROI. The ADC ratio was 
calculated by dividing the ADC ROI by the ADC value obtained from measuring 
a similar small circular ROI  in the contralateral normal brain of contralateral 
hemisphere (Figure 2). 
 
DSC Perfusion  
 
PWI images were obtained with an axial T2* weighted gradient EPI sequence 
(TR 2000 msec, TE 90 msec, FA 30, FOV 34 cm, tk 5mm, spacing 1 mm, 
matrix 128 x 128, 40 phases for slice, 12 slices and acquisition time 1.14 min). 
Contrast media (gadolinium chelate) bolus injection started after the 
completion of the tenth acquisition at a flow rate of 5 ml/sec for a total of 14 
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ml using a 18 Gauges venous access connected to an automatic injector 
Spectris Medrad. Before the PWI acquisition a prebolus of 2 ml of gadolinium 
chelate was administrated to compensate the alteration of the blood-brain 
barrier that is present in some tumours. 
The DSC data were transferred together with the anatomic data to a 
workstation (Advantage Workstation, GE Healthcare) and were analysed by 
using commercial software (FuncTool, GE Healthcare). T2*-weighted signal 
intensity-time curves were derived on a voxel-by-voxel basis. Post hoc 
correction for leakage was performed by using γ-variate curve fitting to 
approximate the curve without recirculation and leakage. Cerebral blood 
volume maps were calculated and coregistered with the axial precontrast and 
post contrast T1-weighted images and with ADC maps. ROI analysis for CBV 
was performed with the same method described for ADC. 
We drew a small circular ROI (approximately 20 mm2) within the enhancing 
lesion that was adjusted onto as necessary to target areas with visually highest 
CBV; the value obtained was recorded as CBV ROI. The relative CBV (rCBV) 
was calculated by dividing the CBV ROI by the CBV value obtained from 
measuring a similar small circular ROI  in the contralateral normal brain of 
contralateral hemisphere (Figure 2). 
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Figure 2. Coregistration of ADC maps, axial precontrast and post contrast T1-weighted images and 
CBV maps. ROIs were positioned in the section containing the maximum diameter of the enhancing 
lesion. 
 
The signal intensity-time curve of the CBV ROI was also used to calculate the 
permeability by determining S0 = precontrast baseline signal intensity, S min = 
minimum signal intensity at the peak of contrast bolus and S1 = end signal 
intensity at 50 seconds (Figure 3). These values were then used to calculate the 
Percentage Signal Recovery (PSR) as follow: PSR = (S1-Smin)/(S0-Smin).  
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Figure 3. CBV ROI positioned in the CBV map (left) with the correspondent signal intensity-time 
curve, on which PSR was calculated (right). 
 
 
Statistical Analysis 
 
Statistical analysis was conducted with R (www.R-project.org/). The results 
with p values of < 0.05 were considered statistically significative. 
Unpaired t-test was used to test difference between progression and responding 
groups for variable : ADC ratio, CE, PSR, rCBV at time T0, T1 and T2. We also 
tested age, incremental ratio of tumor dimensions ((sizeT0 - sizeT1)/sizeT0) 
and duration of radiotherapy.  Fisher’s exact test was performed on categorical 
variable such a gender. 
Significative data were utilized in the univariate logistic regressions adjusted 
for gender and age in order to determine odds ratios (with 95% confidence 
interval) for assessing risk factors. Finally, a multivariate logistic regression 
was performed on univariate significative variables. 
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Results 
 
 
 
The variables ADC ratio, rCBV, CE and PSR were calculated at T0 (before 
surgery), T1 (before RT) and T2 (after RT).   
Unpaired t-test was used to test difference between groups for above 
mentioned variables for each time point, in addition to age, to the incremental 
ratio of the size of the pre and post operative tumor and to the duration of RT. 
The t-test presented statistical significant differences between the groups 
“progression” and “response” at T1 for the variables ADC ratio, PSR and rCBV 
(p value respectively of 0.03, 0.007 and 0.01) (Figure 4). The other variables at 
T1 and the variables calculated at T0 and T2 did not present statistical significant 
differences between the groups.  
The group “pseudoprogression” was not statistically tested because of the small 
number of patients. 
 
Progression Response
1.
0
1.
5
2.
0
A
D
C
Progression Response
2
4
6
8
10
rC
B
V
Prograssion Response
0.
2
0.
4
0.
6
0.
8
P
S
R
 
Figure 4. Box-plots represent significant differences between the groups “progression” and “response” 
respectively for ADC ratio, rCBV and PSR. 
 
The significant data were utilized in the univariate logistic regression in order 
to determine odds ratios (OR) for assessing risk factors.  
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For the group “progression” the univariate analysis with these variables, 
adjusted for gender and age, identified ADC ratio and rCBV as predictors of 
progression. 
In particular, ADC ratio (p = 0.03) presented an OR at 0.080 with a confidence 
interval (C.I.) of 0.008-0.054, while rCBV (p = 0.05) presented an OR at 1.48 
with a C.I. of 0.999-2.198.  
The two predictors mentioned above were used in multivariate analysis, in 
which ADC ratio remained the strongest predictor of progression (p = 0.05) 
with an OR at 0.057 with a C.I. of 0.003-1.009 (Figure 5). 
For the group “response” the univariate analysis with the same variables, 
adjusted for gender and age, identified ADC ratio, rCBV and PSR as predictors 
of response. In particular, ADC ratio (p = 0.04) presented an OR at 11.06 with 
a C.I. of 1.041-117.616, rCBV (p = 0.03) presented an OR at 0.56 with a C.I. 
of 0.335-0.962 and PSR (p = 0.04) presented an OR at 1.00 with a C.I. of 
1.000-1.017. In the subsequent multivariate analysis with these three 
predictors, PSR remained the strongest predictor of response (p = 0.04) with an 
OR at 1.01 with a C.I. of 1.000-1.024 (Figure 6). 
 
 
 
Figure 5. Age- and gender-adjusted and multivariate-adjusted odds ratio and 95% confidence intervals of 
variables for the group “progression”. 
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Figure 6. Age- and gender-adjusted and multivariate-adjusted odds ratio and 95% confidence intervals of 
variables for the group “response”. 
 
 
 
 
 
Discussion 
 
 
The RANO criteria were proposed in 2010 by the RANO Working Group with 
the purpose of overcoming the limitations of previous Macdonalds criteria [6]. 
The main innovations consist in the introducion of nonenhancing lesions (only 
observable in T2-weighted images) in the evaluation of MR images and in 
adding a better definition of how to take measurements of enhancing lesions..	
Currently this type of evaluation, in association with the clinical condition of 
the patient, determines whether there has been a progression of the disease, a 
partial response, a complete response or stability of the disease. 
The RANO criteria also introduce the assessment of the effects of 
chemoradiotherapic treatment, in particular the phenomena of 
pseudoprogression and pseudoresponse [6]. 
Pseudoprogression is a subacute treatment-ralated change characterized by a 
transient increase of contrast enhancement, after irradiation and chemotherapy 
with temozolomide, in the absence of tumor. It usually develops <6 months 
	 17	
after RT with self-limited enhancing lesions that spontaneously stabilize and 
resolve within 2-6 months without any new treatment [19]. This phenomenon 
is most likely induced by a pronounced local tissue reaction with an 
inflammatory component, oedema and abnormal vessel permeability causing 
new or increased contrast enhancement on MR imaging examinations [20]. 
Transient increases in contrast enhancement just after completion of 
chemoradiotherapy play an important role in clinical management of patients 
with cancer because they complicate the ability of physician to determine 
whether to continue with standard adjuvant chemotherapy or to switch to a 
second-line therapy for recurrence. Thus, the detection of pseudoprogression 
versus true progression is a critical important issue in oncology practice [20]. 
In our cohort of patients we have identified 3 patients with pseudoprogression, 
in which we observed the appearance of an enhancing lesion at MR imaging at 
T2 after 1 month of the end of RT with net reduction or complete disappearance 
in the subsequent MR controls (Figure 7). 
Because of the small number of these patients, it was not possible to perform 
statistical tests to determine the role of the advanced MR techniques in the 
differential diagnosis between pseudoprogression and progression neither to 
test if advance MR parameters might constitute a predictor for future 
development of pseudoprogression. 
However, several studies have revealed that advanced MR techniques allow to 
differentiate pseudoprogression and true progression. Mangla et al. [21] and 
Tsien et al. [22] demonstrated a reduction in rCBV in patients with 
pseudoprogression and an increse in rCBV in tumor progression. Prager et al. 
[19] found higher diffusion and lower perfusion values in treatment-related 
changes, and in particular in pseudoprogression, than in recurrent tumour, in 
patients with HGGs and these results reflect the lower cellularity and 
vascularity of treatment-related changes, respectively, and suggest that DWI 
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and DSC perfusion are useful tools in discriminating treatment-related changes 
from recurrent tumour.  
The above-mentioned characteristics were identified also in 3 patients of our 
cohort (Figure 7). 
 
               
 
Figure 7. A case of pseudogrogression. Appearance of an enhancing lesion at MR imaging after 
about 1 month after the end of RT with complete disappearance in the subsequent MR control. 
 
With regard to the phenomenon of pseudoresponse, antiangiogenic agents, 
especially those targeting vascular endothelial growth factor (VEGF), such as 
bevacizumab, and the VEGF receptor, such as cediranib, can produce marked 
decrease in contrast enhancement as early as 1 to 2 days after initiation of 
therapy and commonly result in high radiologic response rates of 25% to 60% 
[23-26]. These apparent responses to antiangiogenic therapy may be partly a 
result of normalization of abnormally permeable tumor vessels and not always 
necessarily indicative of a true antiglioma effect. As a result, radiologic 
responses in studies with antiangiogenic agents should be interpreted with 
caution. For this reason, the RANO criteria suggest that radiologic responses 
should persist for at least 4 weeks before they are considered as true responses 
[6]. 
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In our cohort, one patient receiving bevacizumab presented pseudorensponse. 
In this patient, the decrease of contrast enhancement and of rCBV after the 
initiation of the therapy could be interpreted as a response, but at T2-weighted 
images we observed an extensive neoplastic diffusion with bilateral 
nonenhancing and not measurable lesions, confirmed by MR Spectroscopy 
Imaging (Figure 8). 
 
 
 
Figure 8. A case of pseudoresponse. Reduction of contrast enhancement and of rCBV after therapy; 
in T2-weighted images, extensive neoplastic diffusion with bilateral nonenhancing and not 
measurable lesions, confirmed by MR Spectroscopy Imaging extends beyond the corpus callosum 
indicating tumour progression despite the disappearance of contrast enhancement. 
 
 
 
The RANO criteria allows to establish the presence of progression or response 
only after chemoradiotherapy.  
In recent years various prognostic genetic markers have been identified in 
GBM, including methylation status of the gene promoter for O6-
methylguanine-DNA methyltransferase (MGMT), isocitrate dehydrogenase 
enzyme 1/2 (IDH1/2) mutation, epidermal growth factor receptor (EGFR) 
overexpression and amplification, glioma-CpG island methylator phenotype 
(G-CIMP), tumor protein (TP53) mutation and genetic losses of chromosomes 
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[27]. For example, it has been amply demonstrated that methylation of MGMT 
causes silencing of the gene and interference with DNA repair and increases 
TMZ sensitivity while an unmethylated promoter for MGMT, results in active 
gene expression and high levels of the repair enzyme that results in 
chemotherapy resistance [28,29]. It is also known that IDH1 mutated high 
grade gliomas arise by transformation from lower-grade gliomas and have 
distinguishing radiographic, histologic and transcriptional features (frontal 
location and lesser extent of contrast enhancement and necrosis) that are 
consistent with a less aggressive clinical course. IDH1 mutated high grade 
gliomas have a more favourable prognosis than the ones without IDH1 
mutation [27,30]. 
The results of the present study suggest that MR advanced techniques allow us 
to identify some predictors of response or progression to chemoradiotherapy in 
patients with High Grade Gliomas, in particular DWI and DSC perfusion at T1 
or rather in the MR examination after surgery and before the start of the 
therapy. 
Diffusion and perfusion MR imaging provides physiologic information that is 
not available with conventional MR imaging [19]. DWI measures the motility 
of water molecules and alterations in the balance of intracellular and 
extracellular water restricted by cell membranes and other structures. Areas of 
diffusion restriction in tumours are correlated with increased tumour cellularity 
[31]. The greater is the cellularity of the tumour and the lowest is the ADC 
value, because the diffusivity of water is reduced in consequence of the relative 
decrease of the extracellular space for the movement of protons. Studies carried 
out by Bulakbasi et al [32], Fan et al [33] and Arvinda et al [34] have shown 
that there is inverse correlation between the degree of gliomas and ADC: 
higher is the tumour cellularity and grade of glioma, lower is the ADC value. 
DSC MR perfusion is an advanced technique that provides independent 
	 21	
information on neoangiogenesis, vascular attenuation, and microvascular 
leakiness [20,21]. These features are indicative of the aggressiveness of tumors 
and, as demonstrate by several studies, high-grade gliomas have a greater 
degree of perfusion and rCBV compared to those low-grade, due to a major 
neoangiogenesis [34-40]. 
In recent years, some authors have tried to determine if MR advanced 
techniques can be used to predict the patient response to concurrent 
chemoradiotherapy with temozolomide, evaluating contrast-enhancing lesions 
detected on immediate post-operative MR imaging. Lee et al [41] showed that 
the normalized CBV (nCBV) on immediate post-operative MR imaging was 
significantly higher in the progression group than in the non-progression group 
(p = 0.033) and so it may be feasible for predicting glioblastoma response to 
chemoradiotherapy with temozolomide. In the mentioned-above study 
normalized ADC and other parameters evaluated showed no significant 
differences between the two groups and the could not be used to predict the 
treatment response. Kim et al [42] showed that nCBV value can be used for the 
prognosis prediction of a measurable enhancing lesion after the completion of 
standard treatment for GMB, wherein a high 99th percentile nCBV value 
(>4.5) suggests a better PFS for GBM patients. Conversely, a low 99th 
percentile nCBV values seem to indirectly reflect hypoxic conditions, which 
could make cancer cells more aggressive and resistant to treatment. Also in this 
study ADC was not significantly different between the two groups. 
In our study, for the group “progression” the univariate analysis, adjusted for 
gender and age, identified ADC ratio and rCBV as predictors of progression 
with OD respectively of 0.080 and 1.48 and C.I. respectively of 0.008-0.054 
and 0.999-2.198. In the subsequent multivariate analysis only ADC ratio 
remained the strongest predictor of progression (p = 0.05) with an OR at 0.057 
with a C.I. of 0.003-1.009. 
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According to the results of our study, a low ADC ratio at T1 before the 
initiation of therapy implicate a higher probability of a progression of the 
disease after chemoradiotherapy. 
For the group “response” the univariate analysis, adjusted for gender and age, 
identified ADC ratio, rCBV and PSR as predictors of response with OD 
respectively of 11.06, 0.56 and 1.00 and C.I. respectively of 1.041-117.616, 
0.335-0.962 and 1.000-1.017. In the subsequent multivariate analysis only PSR 
remained the strongest predictor of response (p = 0.04) with an OR at 1.01 with 
a C.I. of 1.000-1.024. 
PSR is a measure of permeability influenced by leakage of contrast and the size 
of the extravascular space, with lower PSR reflecting higher permeability [19]. 
Capillary permeability is another feature of angiogenesis in high-grade 
gliomas. PSR, obtained from a DSC perfusion MR technique, gives similar 
information to  Ktrans obtained with DCE perfusion, which is an estimation of 
the capillary permeability based on measuring the contrast leakage rate 
between the intravascular and extravascular spaces. Several studies showed 
that it generally correlates with histological grading and length of survival in 
gliomas [43-47]. 
According to the results of our study a high value of PSR at T1 before the 
initiation of therapy implicate a higher probability of a response of the patients 
after chemoradiotherapy. 
Apart from the intrinsic limits of any retrospective study, a number of other 
limitations of the present study should be mentioned. First, this study included 
a small number of patients and this might have resulted in selection bias. The 
small number of the patients is due to the rigidity of the inclusion criteria; 
furthermore, often follow-up examinations are not performed in the same 
centre and, if performed in periferic centres, perfusional study is not present. 
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Therefore, large population studies are required to validate our results. Second, 
we used multiple MRI scanners with different field strnght (1.5 and 3.0 T 
scanners) and the scan parameters are slightly different for each machine. 
Although we normalized the CBV and ADC values to minimize the effects of 
the different magnetic field strengths, there could be a slight bias in the image 
analysis of the ADC and CBV maps. 
 
 
 
Conclusions 
 
MR advanced techniques, in particular diffusion with ADC and perfusion with 
PSR, have proved a valuable aid in predicting respectively progression and 
response of glioblastomas to chemoradiotherapy. 
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